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Abstract
Background: Upregulation of the plasminogen activation system, including urokinase 
plasminogen activator (uPA), has been observed in many malignancies, suggesting 
that co-opting the PA system is a common method by which tumor cells accomplish 
extracellular matrix proteolysis. PAI-2, a serine protease inhibitor, produced from the 
SERPINB2 gene, inhibits circulating and extracellular matrix-tethered uPA. Decreased 
SERPINB2 expression has been associated with increased tumor invasiveness and 
metastasis for several types of cancer. PAI-2 deficiency has not been reported in 
humans and PAI-2-deficient (SerpinB2−/−) mice exhibit no apparent abnormalities.
Objectives: We investigated the role of PAI-2 deficiency on tumor growth and 
metastasis.
Methods: To explore the long-term impact of PAI-2 deficiency, a cohort of SerpinB2−/− 
mice were aged to >18 months, with spontaneous malignancies observed in 4/9 
animals, all of apparently vascular origin. To further investigate the role of PAI-2 
deficiency in malignancy, SerpinB2−/− and wild-type control mice were injected with 
either B16 melanoma or Lewis lung carcinoma tumor cells, with markedly acceler-
ated tumor growth observed in SerpinB2−/− mice for both cell lines. To determine the 
relative contributions of PAI-2 from hematopoietic or nonhematopoietically derived 
sources, bone marrow transplants between wild-type C57BL/6J and SerpinB2−/− 
mice were performed.
Results and Conclusions: Our results suggest that PAI-2 deficiency increases suscep-
tibility to spontaneous tumorigenesis in the mouse, and demonstrate that SerpinB2 
expression derived from a nonhematopoietic compartment is a key host factor in 
the regulation of tumor growth in both the B16 melanoma and Lewis lung carcinoma 
models.
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1  | INTRODUC TION
Components of the plasminogen activation (PA) system, in-
cluding urokinase plasminogen activator (uPA), are thought 
to play key roles in malignant tumor growth and metastasis.1 
Plasminogen activator inhibitor 2 (PAI-2), a serine protease in-
hibitor (SERPIN) produced by the SERPINB2 gene, is a potent 
inhibitor of uPA.1 PAI-2 is a predominantly intracellular SERPIN 
whose expression is induced by inflammatory mediators.2 It 
is one of the most highly upregulated transcripts in activated 
macrophages and keratinocytes and is also highly inducible in 
fibroblasts and endothelial cells.2 PAI-2 exists in two forms: a 
47-kD nonglycosylated intracellular form, and a secreted 60-kD 
glycosylated form, though neither is generally detectable in 
plasma, except during pregnancy.3 The regulation of SERPINB2 
gene expression is complex, with known induction by a variety 
of inflammatory molecules including tumor necrosis factor alpha 
(TNF-α) and lipopolysaccharide.2 Though PAI-2 is an efficient 
inhibitor of uPA, additional target proteases may exist in vivo, 
including several putative intracellular proteases.2,4
Clinical studies in breast, lung, and ovarian cancer patients 
have shown a striking correlation of low tumor-associated PAI-2 
levels with poor prognosis, including increased lymph node in-
volvement and decreased overall survival.2,5,6 Expression of 
SERPINB2 in several cell types in the context of the local tumor 
environment could potently prevent malignant cell invasion.7 
Extracellular matrix degradation by colon carcinoma and mono-
cyte invasion into human amniotic membranes is inhibited in 
the presence of exogenous PAI-2.8 Transfection of SERPINB2 
into melanoma and sarcoma cell lines resulted in decreased 
ability to degrade extracellular matrix and a reduced capacity 
for metastasis.2 Similarly, gene transfer of SerpinB2 into the 
liver was demonstrated to reduce fibrosarcoma primary tumor 
size in nude mice and significantly decrease the incidence of 
metastasis.2 In addition, the plasminogen activation system has 
been demonstrated to play a prominent role in tumor progres-
sion in the mouse transplantable B16 melanoma and Lewis lung 
carcinoma tumor models.2,9,10 Taken together, these observa-
tions suggest that localization of PAI-2 within the tumor mi-
croenvironment may play an important role in the regulation of 
tumor growth.
Though PAI-2 deficiency has not been reported in humans, 
PAI-2-deficient (SerpinB2−/−) mice exhibit normal development 
and survival, as well as normal wound healing and response to 
infectious challenge.11 In the present study, spontaneous tumors 
were observed in a subset of aging SerpinB2−/− mice (>1 year of 
age). Analysis of wild-type (WT) control and SerpinB2−/− mice 
challenged by injection with either B16 melanoma or Lewis lung 
carcinoma (LLC) cells, as well as chimeric animals generated by 
bone marrow transplant (BMT), suggest that SerpinB2 expres-
sion within a nonhematopoietically derived host compartment 
plays a key role in the limitation of tumor growth and metastasis 
in the mouse.
2  | RESULTS
2.1 | Spontaneous tumor development in 
SerpinB2−/− mice
A cohort of 9 male SerpinB2−/− mice were observed until the cutoff 
date of 22 months of age with 44% (4 of 9) developing a spontane-
ous malignant tumor between 18 and 22 months. Three of these 
four tumors exhibited the histological appearance of angiosarco-
mas (Figure 1), with one tumor originating in the liver, another in 
the periarticular region of the hip, and one in both the liver and the 
flank. The fourth animal developed a large polyploid tumor in the 
dorsal flank that was classified as a fibrosarcoma. In contrast, as 
reported by Rudolph et al, the expected rate of spontaneous tu-
mors in a mixed B6129 background (similar to the aged SerpinB2−/− 
mice), is ~ 3% (2 of 63) mice. In addition, the SerpinB2−/− mice had 
a higher rate of spontaneous tumor formation than homozygous 
telomerase-deficient mice (mTR−/−) and unlike the more common 
tumor types observed in aging B6129 mice, exhibited rare angio- 
and fibrosarcomas.12,13
2.2 | Enhanced growth of heterologous tumors in 
SerpinB2−/− mice
To investigate the role of PAI-2 in the host response to exogenously 
introduced tumor cells, male SerpinB2−/− mice and littermate controls 
from an intercross of SerpinB2± mice backcrossed three generations 
to C57BL/6J (N3) were challenged by left hind footpad inoculation of 
B16 melanoma cells14 (derived from C57BL/6J mice). All 7 SerpinB2−/− 
mice and three of five WT littermate controls developed visible tu-
mors by 34 days postinoculation, with significantly larger tumor size 
observed in the SerpinB2−/− mice (Figure 2A; mean tumor volume in 
SerpinB2−/− recipients = 292 ± 58 mm3 vs WT control mice = 16 ± 
9 mm3; P < .003). In addition, two of seven SerpinB2−/− mice devel-
oped numerous lung metastases with chest wall involvement, with 
no lung metastases observed among the five WT controls. The local 
footpad tumors in the SerpinB2−/− mice appeared highly invasive, 
with infiltration between smooth muscle bundles and extension into 
the subepidermal layer, in contrast to a circumscribed appearance in 
Essentials
• Low PAI-2 (SERPINB2) is associated with increased 
tumor growth and metastasis.
• Aged PAI-2 deficient (SerpinB2−/−) mice spontaneously 
develop tumors.
• SerpinB2−/− mice display accelerated B16 melanoma or 
Lewis lung carcinoma growth.
• Non-hematopoietic PAI-2 regulates B16 melanoma and 
Lewis Lung carcinoma tumor growth.
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the WT mice (Figure 3A-D). In two SerpinB2−/− mice, the inoculated 
footpad melanoma extended into the leg and hip, a finding not seen 
in any of the five control mice.
To address the potential confounding effects of the mixed 129/
C57BL/6J strain background, a second set of experiments were 
conducted in mice after 7 backcross generations into C57BL/6J 
(N7), including 9 SerpinB2−/− mice, 8 heterozygous SerpinB2± lit-
termates, and 13 WT littermate controls. Visible tumors devel-
oped in 8/13 WT, 9/9 SerpinB2−/−, and 8/8 heterozygous mice 
(Figure 2B). Numerous lung metastases developed in three of nine 
SerpinB2−/− mice, but in none of the heterozygotes or WT con-
trols. A significant increase in mean local tumor volume was again 
observed in SerpinB2−/− mice compared to WT controls with in-
termediate values in the heterozygotes (Figure 2B; mean tumor 
volume: SerpinB2−/− 214 ± 42 mm3, SerpinB2± 83 ± 20 mm3, WT 
31 ± 13 mm3). One SerpinB2−/− mouse was euthanized at day 28 
because of extensive tumor invasion from the footpad into the leg, 
and was excluded from evaluation.
Similar sets of experiments were performed in SerpinB2−/− and 
WT mice using LLC injected either into the footpad or intradermally 
on the back (Figure 2C,D). A highly significant increase in local tumor 
growth was observed in N3 SerpinB2−/− mice compared with WT lit-
termate controls at both sites of tumor administration, associated 
with a more invasive histological appearance (Figure 3E,F). Two of 
four SerpinB2−/− mice inoculated intradermally exhibited progres-
sion of LLC tumor to the spine, a finding not seen in any of the WT 
controls.
2.3 | The optimal host response to injected B16 
melanoma or LLC tumor cells requires SerpinB2 
expression by nonhematopoietically derived host cells
SerpinB2 is highly expressed in macrophages,15-17 suggesting a po-
tential role for these or other hematopoietically derived cells in the 
host responses to B16 melanoma and LLC observed above. To test 
this hypothesis, BMT was performed into N7 SerpinB2−/− recipients 
and age and sex-matched WT littermate controls using either donor 
SerpinB2−/− or WT fetal liver cells (FLC). All four sham-transplanted 
mice died within 4 days of irradiation, demonstrating effective my-
eloablation. There was no mortality among the other transplanted 
groups. WT mice receiving SerpinB2−/− FLC should be SerpinB2-
deficient in all cell populations of hematopoietic origin with normal 
expression in all other cell types, whereas SerpinB2−/− mice reconsti-
tuted with WT FLC should exhibit the converse pattern, with nor-
mal SerpinB2 expression restricted to cells of hematopoietic origin 
including monocytes/macrophages (Figure 4). Footpad injections of 
B16 melanoma cells were performed 6 weeks after BMT SerpinB2−/− 
mice reconstituted with WT FLCs demonstrate accelerated tumor 
growth similar to that observed in untransplanted SerpinB2−/− mice 
or SerpinB2−/− mice reconstituted with SerpinB2−/− FLCs (Figure 4; 
compared with Figure 2B). In contrast, WT mice receiving either 
SerpinB2−/− or WT FLCs exhibited reduced tumor volume (Figure 4), 
similar to untransplanted WT mice (Figure 2).
3  | DISCUSSION
Although decreased SerpinB2 expression has been repeatedly asso-
ciated with poor cancer prognosis,2 the role of PAI-2 in human tu-
mors is unclear. In a comprehensive analysis of multiple cancer types, 
mutations in SERPINB2 were not identified as “tumor drivers.”18 
Similarly, heterozygosity for germline SerpinB2 loss-of-function mu-
tations is observed in the general population with a frequency of 
~1:2500,19 and would be expected to result in a familial cancer pre-
disposition syndrome with a similar frequency, if PAI-2 functioned as 
a tumor suppressor.
These data suggest a regulatory function for SerpinB2 expres-
sion in nontumor cell types, potentially playing a role in host de-
fense. Consistent with this hypothesis, analysis of PAI-2 in tumor 
sections is associated with stromal cells such as endothelial cell, 
fibroblasts, and macrophages.2 The observation that heterozygous 
SerpinB2± mice demonstrate an invasive B16 melanoma phenotype 
F I G U R E  1   Histological examination of spontaneous tumors 
arising in aged SerpinB2−/− mice. Hematoxylin and eosin staining 
of zinc formalin-fixed, paraffin-embedded tumors pathologically 
defined as angiosarcomas, which developed in the (A) hip and (B) 
liver in two independent animals
A
B
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intermediate between those of SerpinB2−/− and WT mice suggests a 
gene dosage effect.
Given the known expression of SERPINB2 in a number of he-
matopoietically derived cell types, including monocyte/macro-
phages and stem cells,2 the observation that BMT of WT FLCs 
into SerpinB2−/− (or SerpinB2−/− FLCs into WT) mice had no effect 
on B16 melanoma or LLC tumor growth was surprising. These 
data demonstrate that the accelerated tumor growth observed in 
SerpinB2−/− mice is not due to a specific deficiency within the mac-
rophage or another hematopoietically derived cell population, but 
rather from a nonhematopoietically derived source. However, we 
cannot exclude a role for memory T-lymphocytes or tissue phase 
macrophages, which, although hematopoietically derived, turn 
over at very low rates and propagate by self-renewal in tissues.20 
The spontaneous development of tumors in aged SerpinB2−/− mice 
is also consistent with an important role for SerpinB2 gene expres-
sion by a nonhematopoietic host cell compartment in naturally 
occurring cancers, in addition to exogenously introduced cancer 
models. These data raise the possibility of an important role for 
PAI-2 produced by stromal cells within the tumor microenviron-
ment.2 Recently, Harris et al demonstrated that stromal cell PAI-2 
is required for normal collagen remodeling in vitro, establishing a 
novel role for stromal PAI-2 in tumor growth and invasion.21
Mechanistically, it is possible that PAI-2 could affect tumor growth 
via a function unrelated to plasminogen activator inhibition. These 
functional roles could partially or wholly contribute to the inhibition of 
tumorigenesis and growth. The intracellular localization of PAI-2 sug-
gests that it could function to regulate intracellular processes impact-
ing tumor growth.22 For example, PAI-2 has previously been shown to 
inhibit TNF-α-induced apoptosis,23,24 as well as acting as a downstream 
effector of p38 signaling to maintain macrophage survival during 
Bacillus anthracis triggered apoptosis.25 Similarly, PAI-2 has also been 
shown to maintain the survival of TNF-stimulated cells by stabilizing 
transglutaminase 2 through interaction with PAI-2’s C-D interhelical 
F I G U R E  2   Host SerpinB2 status modulates primary tumor size. B16 melanoma or Lewis lung carcinoma was injected into (A-C) the 
left hind footpad or (D) the dorsal intradermal region of each animal. Mice with tumors are represented by solid symbols; mice that did 
not develop tumors are indicated with open symbols. Panels A and B are the results of B16 melanoma experiments; panels C and D are 
the results of the LLC experiments. A. N3 SerpinB2−/− mice had a mean tumor volume = 292 mm3 vs 16 mm3 in WT mice; P < .003. B. N7 
SerpinB2−/− mean tumor volume 214 mm3 vs SerpinB2± 83 mm3; P < .01, SerpinB2± vs WT 31 mm3; P < .01, SerpinB2−/− vs WT P < .001. 
Tumor volumes were calculated at day 34. One SerpinB2−/− mouse was euthanized at day 28 because of extensive tumor spread throughout 
the leg, and was excluded from evaluation. C. Mean footpad LLC volume (day 31) N3 SerpinB2−/− 718 mm3 vs WT 72 mm3; P < .03. D. Mean 
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domain, leading to caspase 3 inactivation by transglutaminase 2 and 
increased survival.26 Loss of PAI-2 may also lead to loss of retinoblasto-
ma-mediated repression of proapoptotic gene transcription, rendering 
stromal cells more sensitive to apoptosis.24,27
In contrast to our results, Schroder et al observed no signif-
icant differences in tumor growth in SerpinB2−/− vs control mice 
injected with LLC or B16 melanoma cells.28 Although these data 
are in direct contrast to those reported here, important differ-
ences in the experimental conditions are worth noting. Exclusively 
5- to 8-week-old male mice were used in our experiments, whereas 
Schroder et al performed their experiments exclusively in female 
mice. Sex significantly affects tumor growth in hepatocellular car-
cinoma and hepatocarcinogenesis in humans and mice.29 SerpinB2 
expression in response to lipoprotein(a) has been shown to be sex 
specific and is only observed in males.30 Thus, sex could contribute 
to the disparities in tumor growth rates between these two stud-
ies. Additional differences in study design include the site of inoc-
ulation (left hind footpad vs subcutaneous back), the numbers of 
cells used in the inoculation (1 × 105 LLC and B16 melanoma in our 
study vs 4-5 × 105 used by Schroder et al). In addition, changes in 
the gut microbiome could play an important role in the differences 
in tumor growth in experiments performed at different institutions. 
Mice lacking endothelial specific Krit1 or Ccm2 exhibit markedly 
different manifestations of cerebral cavernous malformation as a 
function of the gut microbiome, initially uncovered by examination 
of the same mouse colony in two different vivariums.31 Because 
PAI-2 is a stress protein that is highly inducible in activated mac-
rophages and monocytes, similar shifts in microbiome in different 
laboratories could also potentially influence the host response to 
an implanted tumor.
Taken together, our results suggest that nonhematopoieti-
cally derived PAI-2 plays a previously underappreciated role in the 
response to malignancy. Our findings provide the basis for future 
studies on the regulation of tumor growth by PAI-2. Investigating the 
tumor response in mice with specific PAI-2 deficiency in fibroblasts 
or other stromal cellular constituents22-26,32 could provide additional 
insights into the tumorostatic function of PAI-2.
4  | Methods
4.1 | Mice
WT C57BL/6J (stock #000664) mice were purchased from the 
Jackson Laboratories. SerpinB2-deficient mice generated by gene 
F I G U R E  3   Gross and histological examination of footpad tumors 
following injection with B16 melanoma or LLC. Representative 
(A) WT or (B) SerpinB2−/− mice at day 34. Hematoxylin and eosin 
staining of zinc formalin-fixed, paraffin-embedded tissue from a day 
34 footpad tumor of a (C) WT and (D) SerpinB2−/− mouse showing 
a well-circumscribed area of tumor in panel C compared with a 
much more invasive appearance of the melanoma in the SerpinB2−/− 
mouse (D). Similarly, compared with (E) WT, (F) LLC exhibited more 





F I G U R E  4   Hematopoietic SerpinB2−/− does not influence B16 
melanoma growth. MT) experiments were performed using FLCs 
as a source of hematopoietic stem cells. All surviving mice received 
footpad B16 melanoma injections 6 weeks post-BMT, and were 
sacrificed at day 34. Mice with gray symbols represent WT mice 
receiving WT bone marrow; mice with red symbols represent WT 
mice receiving SerpinB2−/− bone marrow. Mice with blue symbols 
represent SerpinB2−/− mice receiving SerpinB2−/− bone marrow. Mice 
with black symbols represent SerpinB2−/− mice receiving WT bone 
marrow. Host SerpinB2−/− mice receiving WT or SerpinB2−/−marrow 
formed significantly larger tumors than the other groups (P < .05). 
Representative samples of SerpinB2 genotype (by PCR of peripheral 
blood) following BMT are illustrated, demonstrating engraftment. 
The upper band represents the SerpinB2– allele and the lower band 
represents the WT SerpinB2+ allele. Mean footpad tumor volume 
of SerpinB2−/− bone marrow recipients was 160.1 mm3 vs WT bone 
marrow recipients, 24.4 mm3; P < .05. Bars indicate standard error 
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targeting as previously reported,11 were backcrossed for three or 
seven generations to C57BL/6J (N3, N7) and then intercrossed to 
generate homozygous null and WT littermate controls. All mice 
were housed in University of Michigan animal housing facili-
ties, and all experiments were performed in accordance with the 
University of Michigan animal use guidelines. Serpinb2 genotype 
was determined by PCR, as previously described.11 Male mice 
between 5 and 8 weeks of age were used in the tumor experi-
ments; the recipient mice used in the transplant experiments were 
8-week-old males.
4.2 | Tumor cell lines
Both the B16-F1 melanoma (B16 melanoma) and LLC cell lines, origi-
nally isolated from a C57BL/6 mouse strain, were purchased from 
the American Type Culture Collection (#CRL-6323 and #CRL-1642, 
respectively). All cell lines were maintained in Dulbecco's modified 
eagle media (Life Technologies) supplemented with 10% fetal calf 
serum, streptomycin, penicillin, and L-glutamine and were passaged 
no more than five times.
4.3 | Tumorigenic assays
For the tumor inoculations, 1 × 105 B16 melanoma or LLC cells in 
40 μL of sterile Hanks Balanced Salt Solution (HBSS; Invitrogen/
ThermoFisher Scientific) were injected into the left hind footpad 
of each animal in an age-matched cohort of WT and SerpinB2-
deficient mice after anesthesia with intraperitoneal pentobarbital. 
All experiments were performed with the operator blinded to the 
genotype of the mice. For the dorsal intradermal tumor inocula-
tions, 1 × 105 LLC cells in 0.1 mL of HBSS were injected. Footpad 
tumors were monitored for 34 days, at which time tumor size was 
measured using calipers, and the volumes were calculated using 
the formula (W2 × L)/2 where W = tumor width and L = tumor 
length.33 This formula approximates the area of an ellipse. After 
tumor measurement, all animals underwent a left hip disarticula-
tion under anesthesia. Incisions were closed using surgical staples. 
All animals were subsequently sacrificed 34 days postoperatively 
to assess lung metastases by gross visual inspection. The tho-
racic cavity was opened via the removal of the sternum and an-
terior ribs. The lungs were then inflated via intratracheal injection 
Fekete's solution and the trachea clamped to prevent backflow. 
The exterior of the lungs and associated thoracic cavity were visu-
ally examined to detect the presence of major lung metastases 
growing into the chest wall. The respiratory system consisting of 
the trachea attached to the right and left lungs was then removed 
from the mice. Surface pulmonary nodules were counted manu-
ally, with the examiner blinded to the genotype of the mouse, as 
previously described.34
Mice receiving dorsal intradermal injections of LLC cells were 
sacrificed 22 days following initial tumor inoculation for tumor 
excision and measurement with calipers. Tumor volumes were cal-
culated as described previously.
4.4 | Bone marrow transplantation
Fetal livers of both sexes were harvested from WT C57BL/6J 
and SerpinB2−/− mice (from an intercross of SerpinB2± mice N7 on 
C57BL/6J) as previously described.35 Briefly, fetal livers were har-
vested at 18.5 days gestation, homogenized, resuspended in cryo-
media (65% Roswell Park Memorial Institute 1640 [RPMI; Invitrogen/
ThermoFisher Scientific], 10% dimethylsulfoxide, 25% fetal bovine 
serum [Invitrogen/ThermoFisher Scientific]), and stored at −80°C 
for future use. Male mice were used as bone marrow recipients. On 
the day of transplantation, all mice received 1300 cGy of radiation 
in two divided doses, 3 hours apart. Each mouse received a total of 
5 × 108 FLCs in a volume of 0.3 mL sterile RPMI via tail vein injection. 
Four mice received radiation only (“sham-transplanted”) followed 
by tail vein injection of 0.3 mL of sterile RPMI. All mice were then 
monitored daily and were euthanized at the onset of severe illness 
(lethargy, ruffled fur). The four sham-transplanted mice died by day 
10 after transplant. At 6 weeks posttransplant, surviving mice were 
injected in the left hind footpad with 1 × 105 melanoma cells in 40 
μL of sterile HBSS, as described previously. On day 34 after tumor 
injection, all animals were sacrificed to evaluate both primary tumor 
volume and gross metastatic tumor spread. To assess engraftment 
of the transplanted mice, DNA was isolated from peripheral blood 
using the Bio-Rad InstaGene Dry Blood kit, and PCR was performed 
as previously described.21
4.5 | Histochemistry
After caliper measurement, tumor specimens were preserved in zinc 
formalin, and 8-μm paraffin sections were stained with hematoxylin 
and eosin.
4.6 | Statistical analysis
The statistical significance of differences between groups was de-
termined by Student's t test. Two-sided P values of <.05 were con-
sidered statistically significant. For the bone marrow transplant 
experiment, a chi-squared test was used.
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